drugset / Trial / NCT01451736
Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia
Phase 4
Completed
146 enrolled
University of California, Los Angeles
Janssen Scientific Affairs, LLC · collabNational Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will determine the efficacy of oral risperidone (Risperdal) versus long-acting injectable paliperidone palmitate (Invega Sustenna) in treating people with first-episode schizophrenia.
Timeline
- Start
- 2011-10
- Primary completion
- 2021-12-01
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Risperidone | Other / unclassified | — | Oral |
| Subject | paliperidone palmitate | Unknown | — | Other |